IPG Health Launches Industry’s First Clinical Trial Diversity Offering
06 Setembro 2023 - 3:00PM
Building on its long-standing commitment to advancing health
equity, and specifically clinical equality, IPG Health formally
launched an industry-first offering designed to help pharma and
healthcare companies diversify their clinical trials and ensure
more inclusive treatment innovations. The new offering is a
multidisciplinary approach that ensures equitable representation
across various dimensions of diversity—from race to gender, age,
and other intersectional groups—throughout the clinical trial
process.
Drawing from IPG Health’s deep medical and engagement strategy,
data analytics, software intelligence, and patient experience
expertise, the end-to-end offering addresses barriers to inclusion
across clinical trial outreach, recruitment, and engagement. This
includes everything from understanding patients’ behaviors and
predicting their health intentions, to crafting measurable
engagement strategies, developing clinical trial support systems,
and more.
“Too often various communities and populations are
underrepresented in clinical trials, even when their lives are at
stake. Take type 2 diabetes, for example—only 4% of type 2 diabetes
clinical trial participants are Black, yet Black Americans are more
likely to experience diabetes complications than White Americans.
And in all clinical trials, less than 1% of participants are Native
American, even though Native Americans are more likely than White
Americans to experience diseases such as type 2 diabetes, obesity,
coronary heart disease, and liver cancer,” said Sommer Bazuro, IPG
Health’s Chief Medical Officer. “And that’s just looking at
disparities along racial lines for only two groups. Excluding any
population from clinical trials means sidelining millions of people
for new treatments that could improve their health outcomes and
potentially save their lives.”
IPG Health has long advocated for diversity in clinical trials,
notably with its award-winning “The Trial for
#ClinicalEquality” campaign, which, for over three years now,
has galvanized cross-sector stakeholders—from physicians, pharma
companies, and advocacy groups to influential tech companies and
academic institutions—to help raise awareness and spur innovation
that effects change.
“We are relentlessly focused on doing what’s right for our
clients, their brands, and our people. And we can’t do what’s right
unless equity, diversity, and inclusion (EDI) are at the heart of
our business,” said IPG Health CEO, Dana Maiman. “This important
offering is just another way that we continue to hold ourselves
accountable for advancing health equity and being trusted partners
to our clients. This clinical trial diversity offering is a pivotal
move in helping clients unlock new opportunities and address
significant unmet needs in underserved populations and, ultimately,
helping to accelerate equity in healthcare.”
Bazuro added: “Helping companies produce truly inclusive clinal
trials and outcomes requires a deep understanding of the innate
complexities of the clinical trial process and the multifactorial
barriers within it. That’s something very few health marketing
agencies possess. At IPG Health, we’ve invested years into
understanding those complexities and variables, and identifying
actionable opportunities. And we do it in partnership with leading
tech and pharma companies, advocacy organizations, and academic
institutions across the full clinical trial spectrum—from the
supply and demand ends to the crucial intermediaries in between.
All of this demands a depth of medical and scientific expertise,
creativity, and specialized capabilities that only IPG Health is
uniquely able to provide.”
The new offering is an extension of IPG Health’s EDI+You
strategy, which includes “inQ” (Inclusion Intelligence Quotient)—a
proprietary integrated strategic framework designed to ensure even
more inclusive experiences and creative solutions across the
network’s 45+ agencies. Rooted in an evidence-based framework
inspired by the World Health Organization’s Determinants of Health
model, IPG Health’s inQ focuses on understanding how multiple
factors and influences impact exclusion or inclusion of people so
that no populations are left behind.
About IPG HealthIPG Health is
a global collective of the world’s most celebrated and
awarded healthcare marketing agencies. We are 6,000+ people
across six continents driven by a healthy obsession with
creating novel marketing solutions and harnessing creativity,
technology, science, and data to inspire behaviors that fuel
better health. With 45+ agencies, including 18+ specialized
units, our integrated approach to the full range of communications
capabilities ensures we can help clients improve outcomes and
quality of life for healthcare audiences around the world. Our
clients include the top 20 global pharmaceutical companies as well
as countless start-ups, biotech companies, biopharma companies, and
a variety of life science
companies. IPG Health companies have earned coveted
accolades in 2023, including “Healthcare Network of the Year” on Ad
Age A-List and the New York Festivals Health Awards, and “Network
of the Year” at the Manny Awards. In 2022, they achieved “Network
of the Year” at the London International Awards, MM+M Awards, Manny
Awards, Clio Health Awards, and the Cannes Lions
Festival. We are part of the Interpublic Group of Companies
(NYSE:IPG). Visit ipghealth.com to learn more.
Contact:Chido
Tsemunhu718-500-0944Chido.Tsemunhu@ipghealth.com
Interpublic Group of Com... (NYSE:IPG)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Interpublic Group of Com... (NYSE:IPG)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024